Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Phage Pharmaceuticals, a clinical-stage manufacturer and developer of therapeutic proteins, has designated David Jackson as new vice president of operations planning. He will be reporting Robert Beckman, CEO of Phage Pharmaceuticals.
Subscribe to our email newsletter
Mr Jackson is expected to take up the responsibility for oversight of the company’s cGMP-certified therapeutic protein manufacturing facility in San Diego.
Most recently, Mr Jackson was the vice president of process development and manufacturing at VaxInnate Corporation, where he was responsible for creating development, QA/QC, and regulatory teams, and as well as for building the company’s infrastructure and overseeing capital projects.
He previously was vice president of US operations and later vice president of Global Biologics Manufacturing at Lonza Biologics, a wholly-owned subsidiary of Lonza Group (Switzerland), where he was responsible for green-field site construction and other capital projects, as well as technology transfer and GMP contract manufacturing.
He also served as vice president of manufacturing at BioReliance Corporation and vice president of manufacturing and pharmaceutical support at EntreMed.